Since the establishment of the ACT4TB/HIV, it has been able to leverage a number newly awarded grants
relating to i.) TB adjunctive Host Directed Therapies; ii.) Once weekly isoniazid and rifapentine 3HP; iii.) MDRTB
and iv.) TB vaccines.
1. A multi-arm proof of concept study of adjunctive host-directed TB therapy (TB HDT).
2. Treatment outcomes, PK and safety of a six month TB treatment regimen with once weekly high dose rifapentine and moxifloxacin in the continuation phase, in HIV-infected patients on ART.
3. Rapid detection of acquired fluoroquinolone hetero-resistance (FQ-R) in MDR-TB.
4. Imatinib dose selection for DR-TB.
5. γ9δ2 T cell protection against TB infection.
6. PHOENIx MDR TB trial entitled “Protecting Household on Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients”.
7. Comparison (in collaboration with AERAS and ACT4TB/HIV) of an electronic Informed Consent Process to the standard paper based approach
8. Qualitative review both the perception of contraceptive providers and provider mediated contraception counselling methods used during the ECHO study
9. IMPAACT4TB (Increasing Market and Public health outcomes through scaling up Affordable Access models of short Course preventive therapy for TB) phases 1 (3HP-DTG-DDI), 2 and 3